The Oxthera way

OxThera is a biopharmaceutical company with products in late stage clinical development focusing on Primary and Secondary Hyperoxaluria. OxThera’s intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria, and enzymes. Oxabact® holds Orphan Drug designations in Europe and in the US for the treatment of primary hyperoxaluria.

OxThera AB

Postal address

c/o Ekonomi Klara Papper AB
P.O. Box 1062
SE-101 39 Stockholm

Visiting address

Regeringsgatan 111
SE-111 39 Stockholm

Phone +46 8 660 02 23

Board of Directors

Georges Gemayel, PhD

Georges Gemayel has served as Chairman for OxThera since October 2013. From February 2011 to December 2012, Dr. Gemayel served as executive chairman of Syndexa Pharmaceuticals Corp., a privately held drug development company. Prior to that, in 2010 Dr. Gemayel served as executive chairman of FoldRx Pharmaceuticals, Inc. until its acquisition by Pfizer Inc. From June 2008 until November 2009, Dr. Gemayel served as president and chief executive officer of Altus Pharmaceuticals Inc., a publicly traded pharmaceutical company. From 2003 to 2008, he was executive vice president at Genzyme Corporation where he was responsible for Genzyme Corporation’s global therapeutics, transplant, renal and biosurgery businesses. Dr. Gemayel currently serves as chairman of the boards of directors of Enterome Bioscience SA and Orphazyme ApS, both privately held companies, and on the boards of directors of Dimension Therapeutics, Momenta Pharmaceuticals, and Supernus Pharmaceuticals, Inc.

Dr. Gemayel received his doctorate in pharmacy from St. Joseph University in Beirut, Lebanon and his Ph.D. in pharmacology from Paris-Sud University in Paris, France.

Martijn Kleijwegt

Martijn Kleijwegt founded Life Sciences partners (LSP) in 1998 and is currently a Managing Partner and co-owner of the firm. His prime focus and responsibility within LSP is to invest in unlisted securities and in the general management of the firm. Prior to establishing LSP, Martijn ran another investment firm where he was responsible for investments in the healthcare sector. As one of Europe’s most experienced healthcare investors, Martijn brings over 30 years of hands-on finance and investment experience to the LSP team. He has also been appointed Director of a large number of companies, amongst others Qiagen GmbH, Crucell N.V., Movetis N.V., Prosensa Holding N.V. and Kiadis Pharma, all of which he helped to grow and flourish.

Rémi Droller

Managing Partner at Kurma Partners, Rémi was previously Partner at Idinvest Partners where he developed investment activity in the life sciences. Rémi serves on the board of AM Pharma, Bioalliance Pharma (listed on Euronext) and STAT Diagnostica. He holds a MS in molecular biology (Paris VI University) and MS in finance and Innovation management (AgroPariTech).

Laia Crespo, PhD MBA

Laia is Investment Director in Ysios Capital. She has been Board Observer at AM-Pharma and currently serves on the board of Inbiomotion and Minoryx Therapeutics. Prior to joining Ysios she assessed commercial and scientific license opportunities as part of the European New Business Development team of Janssen-Cilag, a pharmaceutical company of the Johnson & Johnson group.

Laia developed her professional career primarily in the biotechnology cluster of Cambridge, UK, in companies such as Spirogen (now AstraZeneca), Medivir and UCB-Celltech. She holds a PhD in Chemistry from the University of Barcelona and an MBA from Cambridge Judge Business School, University of Cambridge.

Sten Verland, MSc, PhD

Dr. Verland is a Partner of Sunstone Life Science Ventures and one of the three co-founders of Sunstone. Dr. Verland has been active as a serial entrepreneur and business angel and has co-founded ten start-ups, primarily in the biotech and CRO fields. Dr. Verland has played a key role in executing two M&As (Action Pharma and Zymenex). He currently serves on the Board of Directors of Orphazyme A/S, Rigontec GmbH, Vaximm AG, Anergis SA, Minervax APS and the Danish Venture Capital Association, as well as an observer to the Board of Directors of F2G Ltd.

Dr. Verland holds a Master’s degree in Biology and Mathematics and a PhD in Immunology – both from the University of Copenhagen.

Maarten de Chateau, MD, PhD

Co-founder and CEO of Cormorant Pharmaceuticals developing an immuno-oncology mAb, acquired by Bristol-Myers Squibb in 2016. Prior to that, Medical Director at Swedish Orphan Biovitrum, with medical/clinical development responsibility for two marketed products in the rare disease space. Worked in clinical development at Sanofi and also as a financial analyst at two investment banks for five years.

Jonas Brambeck

Investment Manager Life Science at Industrifonden. Dr Brambeck has close to twenty years experience from venture capital within Life Science. He serves on the Board of Directors of Oncopeptides AB, OxThera AB and Athera Biotechnologies AB. He holds a Ph.D. in organic chemistry from The Royal Institute of Technology in Stockholm.

Khalid Islam, PhD

Dr. Khalid Islam has over 29 years of experience in the pharmaceutical and biotechnology industry and is the Managing Director of Life Sciences Management GmbH. Previously, Dr. Islam served as chairman and CEO of Gentium S.p.A. . Under his leadership Gentium completed a $1billion in a cash merger with Jazz Pharmaceuticals, plc. From 1999-2008, he was president and CEO of Arpida AG, a SWX-listed company and raised $300M in the IPO and follow-ons. Dr. Islam is currently the chairman of the Board of Directors of Fennec Pharma and Minoryx Therapeutics and is a member of the Board of Directors of Karolinska Development.

Dr. Islam is a graduate of Chelsea College and received his PhD from Imperial College, University of London. He holds several patents and has published over 80 articles in leading journals.


Matthew Gantz, MBA

CEO of OxThera AB. Former PathoGenesis, Chiron and BTG executive, who has built and led several successful high growth businesses in the US and Europe across the specialty pharma and medical device space in multiple therapeutic areas. Gained approval and successfully launched two rare disease drugs, TOBI and Voraxaze, in Europe and US respectively. Board member of SOBI, a publically listed Swedish Rare Disease Company and Life Sciences PA, the Pennsylvania Life Science industry association.

Mr Gantz is a graduate of Princeton University and received his MBA from Harvard Business School. He also served as an infantry officer in the US Marine Corps.

Elisabeth Lindner, MSc, MBA

COO of OxThera AB. Member of the Royal Swedish Academy of Engineering Sciences. Mrs Lindner has long-term senior management experience from Pharmacia Corporation, Octapharma, and Diamyd Medical among others. She also serves on the Board of Directors for Cobra Biologics Holding AB. Mrs Lindner holds a MSc from the Royal Institute of Technology and a MBA from Uppsala University.

Bastian Dehmel, MD

Chief Medical Officer of OxThera AB. Dr Dehmel has extensive experience in the life science sector, having led Medical Affairs and Clinical Development teams responsible for drugs in Diabetes and End Stage Renal Disease at companies like GSK, Novo Nordisk and Amgen. Dr Dehmel joins OxThera after serving as Executive Medical Director and Global Development Leader for Amgen’s calcimimetic franchise. He brings extensive experience in working with global regulatory agencies and was responsible for FDA and EMA approval of etelcalcetide, and more recently for the orphan pediatric drug approval of cinacalcet by EMA. Dr Dehmel received his medical training in Internal Medicine while at the Charite University in Berlin.